Memorial Sloan Kettering Pancreas Cancer Symposium 2020: Current and Future
Memorial Sloan Kettering Pancreas Cancer Symposium 2020: Current and Future is organized by Memorial Sloan Kettering Cancer Center (MSKCC) and will be held on Mar 20, 2020 at Mortimer B. Zuckerman Research Center, New York City, New York, United States of America.
Pancreas adenocarcinoma is on the rise. Treatment paradigms are changing and many novel approaches are under development in this disease. This one day course in conjunction with the Center for Pancreas Cancer Research (CPCR) at Memorial Sloan Kettering (MSK) is very timely and will review the epidemiology, genomic, molecular and pathologic underpinnings of this disease along with discussing diagnostic and therapeutic approaches for localized, locally advanced and metastatic pancreas adenocarcinoma. An emphasis will be on multidisciplinary decision making and will include a case-based focus. The course will also discuss novel treatments and emerging directions.
The course is designed for medical and surgical oncologists, gastroenterologists, internal medicine specialists, pathologists, geneticists, pharmacists, supportive care staff, nursing, advanced practice practitioners, trainees and other disciplines.
In partnership with the David M. Rubenstein Center for Pancreatic Cancer Research.
Live Simulcast Available*
We are pleased to offer a live simulcast for this symposium, available to non-MSK employees. CME and ABIM MOC credit is offered for the live simulcast and active participation is required throughout the course. We do hope you will attend in person but understand that can sometimes be a challenge, so we are happy to offer the live simulcast as an option. Registration for the simulcast is required; please select the "Live Simulcast" option during course registration. A link to view the Symposium will be emailed to you the day before the course begins.
By attending this symposium, attendees will:
• Enhance understanding of the pathologic, genetic and molecular contexts of pancreas adenocarcinoma
• Improve the understanding related to the needs for genetic testing both germline and somatic for pancreas adenocarcinoma
• Describe the recommended diagnostic approaches for pancreas adenocarcinoma
• Improve multidisciplinary decision-making
• Recognize the indications for neoadjuvant treatment in pancreas adenocarcinoma
• Improve an understanding of emerging novel treatment approaches for pancreas adenocarcinoma.
|Contact No. :||646-227-2025
|Registration Type||Last Date||Price|
|Physicians (MDs, PhDs and DOs) Fee||20 Mar,2020||USD 325.00|
|Advanced Practice Providers Fee||20 Mar,2020||USD 175.00|
|Residents, Fellows, Nurses and Other Healthcare Providers Fee||20 Mar,2020||USD 175.00|
|Industry Professionals Fee||20 Mar,2020||USD 575.00|
|Live Simulcast Fee||20 Mar,2020||USD 525.00|